



Contents lists available at ScienceDirect

International Journal of Antimicrobial Agents

journal homepage: www.elsevier.com/locate/ijantimicag



Corrigendum

Corrigendum to “Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients”. [Int J Antimicrob Agents 51 (2018) 594–600]



Sofie A.M. Dhaese^{a,*}, Jason A. Roberts^{b,c}, Mieke Carlier^d, Alain G. Verstraete^{d,e},
Veronique Stove^{d,e}, Jan J. De Waele^a

^a Ghent University Hospital, Intensive Care, Ghent, Belgium

^b Faculty of Medicine and School of Pharmacy, University of Queensland, Brisbane, Australia

^c Royal Brisbane and Women's Hospital, Brisbane, Australia

^d Ghent University Hospital, Laboratory Medicine, Ghent, Belgium

^e Ghent University, Clinical Chemistry, Microbiology and Immunology, Ghent, Belgium

The authors regret that in the manuscript under the section 2.3 Study Protocol, the following is written:

“This dose was either decreased or increased based on the patient’s kidney function (<15 mL/min: 8/1 g/24 h; 15–30 mL/min: 12/1.5 g/24 h; 30–129 mL/min: 16/2 g/24 h; 130–199: 20/2.5 g/24 h; >200 mL/min: 24/3 g/24h)”

This should read instead:

“This dose was adapted based on the patient’s kidney function (<15 mL/min: 8/1 g/24 h; 15–30 mL/min: 12/1.5 g/24 h; >30 mL/min: 16/2 g/24 h)

The authors would like to apologise for any inconvenience caused.

DOI of original article: [10.1016/j.ijantimicag.2017.12.015](https://doi.org/10.1016/j.ijantimicag.2017.12.015)

* Corresponding author: Sofie A.M. Dhaese, Ghent University Hospital, Intensive Care, C. Heymanslaan, 10, 9000 Ghent, Belgium.
E-mail address: sofie.dhaese@ugent.be (S.A.M. Dhaese).